JP2000503666A - Mappia foetidaから単離したカンプトセシン―骨格化合物および新規な医薬ならびに治療薬のためのシントンとしてのその使用 - Google Patents
Mappia foetidaから単離したカンプトセシン―骨格化合物および新規な医薬ならびに治療薬のためのシントンとしてのその使用Info
- Publication number
- JP2000503666A JP2000503666A JP9540447A JP54044797A JP2000503666A JP 2000503666 A JP2000503666 A JP 2000503666A JP 9540447 A JP9540447 A JP 9540447A JP 54044797 A JP54044797 A JP 54044797A JP 2000503666 A JP2000503666 A JP 2000503666A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- camptothecin
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title claims abstract description 16
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims abstract description 16
- 229940127093 camptothecin Drugs 0.000 title claims abstract description 16
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 241000060384 Mappia Species 0.000 title description 2
- 239000003814 drug Substances 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 241000261227 Mappia foetida Species 0.000 claims abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 10
- -1 phenoxy, amino Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000002028 Biomass Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001769 aryl amino group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 1
- 229910052776 Thorium Inorganic materials 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 238000002955 isolation Methods 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000001212 derivatisation Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- SARNOWGPKQIWFT-FQEVSTJZSA-N (2s)-2-hydroxy-2-[8-(hydroxymethyl)-9-oxo-11h-indolizino[1,2-b]quinolin-7-yl]butanoic acid Chemical compound C1=CC=C2C=C(CN3C4=CC(=C(C3=O)CO)[C@](O)(C(O)=O)CC)C4=NC2=C1 SARNOWGPKQIWFT-FQEVSTJZSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 description 1
- AKIHYQWCLCDMMI-VMPITWQZSA-N (E)-p-coumaroylagmatine Chemical compound NC(N)=NCCCCNC(=O)\C=C\C1=CC=C(O)C=C1 AKIHYQWCLCDMMI-VMPITWQZSA-N 0.000 description 1
- WSXJPXFVULHYMX-KRWDZBQOSA-N 7-[(1s)-1-hydroxypropyl]-8-methyl-11h-indolizino[1,2-b]quinolin-9-one Chemical compound C1=CC=C2C=C(CN3C4=CC(=C(C3=O)C)[C@@H](O)CC)C4=NC2=C1 WSXJPXFVULHYMX-KRWDZBQOSA-N 0.000 description 1
- XVMZDZFTCKLZTF-NRFANRHFSA-N 9-methoxycamptothecin Chemical group C1=CC(OC)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 XVMZDZFTCKLZTF-NRFANRHFSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- WSXJPXFVULHYMX-UHFFFAOYSA-N S-Mappicine Natural products C1=CC=C2C=C(CN3C4=CC(=C(C3=O)C)C(O)CC)C4=NC2=C1 WSXJPXFVULHYMX-UHFFFAOYSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下式(1) (式中、Rは、水素原子またはメトキシ基であり;R1は、ヒドロキシ、Mがア ルカリカチオン、好ましくはナトリウムまたはカリウムであるOM基、C1〜C6 アルコキシ基、場合によっては置換されているフェノキシ基、アミノ基、C1〜 C6モノアルキルアミノ基またはアルキル部分が場合によってアミノ基で置換さ れているC2〜C12ジアルキルアミノ基、アリールアミノ基であり;R2は、C1 〜C6アルキル基または、式COR3の基であって、R3がC1〜C6アルキルであ るか場合によっては置換されているフェニルまたはベンジルである)の化合物。 2.Rが水素またはメトキシであり、R1が、ヒドロキシまたはOM基(M=ナ トリウムまたはカリウム)であり、そしてR2がアセチルである、請求項1記載 の化合物。 3.中間体としての請求項2記載の化合物の用途。 4.あらかじめ乾燥させた Mappia foetida の植物バイオマスの、50℃よりも 低い温度での脂肪族ケトンまたは脂肪族エステル、続いて脂肪族アルコールでの 抽出による、請求項2記載の化合物の調製方法。 5.アルカリ培地中でのカンプトセシンのC17ヒドロキシルの選択的アセチル化 による、請求項2記載の化合物の調製方法。 6.公知の方法による請求項2記載の化合物のエステル化またはアミド化を含む 、請求項1記載の化合物の調製方法。 7.抗腫瘍性細胞傷害性医薬の調製のため、請求項1または2記載の化合物を活 性成分として含有する医薬組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT96A000944 | 1996-05-10 | ||
EP96A000944 | 1996-05-10 | ||
IT96MI000944A IT1283635B1 (it) | 1996-05-10 | 1996-05-10 | Composti a scheletro camptotecinico isolati da mappia foetida e loro uso come sintoni per farmaci o come principi attivi |
PCT/EP1997/002244 WO1997043290A1 (en) | 1996-05-10 | 1997-05-02 | Camptothecin-skeleton compounds isolated from mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000503666A true JP2000503666A (ja) | 2000-03-28 |
JP3483257B2 JP3483257B2 (ja) | 2004-01-06 |
Family
ID=11374242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54044797A Expired - Fee Related JP3483257B2 (ja) | 1996-05-10 | 1997-05-02 | Mappia foetidaから単離したカンプトセシン―骨格化合物および新規な医薬ならびに治療薬のためのシントンとしてのその使用 |
Country Status (20)
Country | Link |
---|---|
US (1) | US6121277A (ja) |
EP (1) | EP0912573B1 (ja) |
JP (1) | JP3483257B2 (ja) |
KR (1) | KR20000010893A (ja) |
CN (1) | CN1082509C (ja) |
AT (1) | ATE211140T1 (ja) |
AU (1) | AU715482B2 (ja) |
CA (1) | CA2253914C (ja) |
CZ (1) | CZ287901B6 (ja) |
DE (1) | DE69709357T2 (ja) |
DK (1) | DK0912573T3 (ja) |
ES (1) | ES2169389T3 (ja) |
HK (1) | HK1019600A1 (ja) |
IT (1) | IT1283635B1 (ja) |
NO (1) | NO311839B1 (ja) |
PL (1) | PL188228B1 (ja) |
PT (1) | PT912573E (ja) |
RU (1) | RU2169149C2 (ja) |
SK (1) | SK283050B6 (ja) |
WO (1) | WO1997043290A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2792937B1 (fr) | 1999-04-27 | 2001-08-10 | Cemaf | NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT |
EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
CA2525099A1 (en) | 2003-05-12 | 2004-11-25 | Purdue Research Foundation | Cytotoxic indeno and isoindoloisoquinolones |
ITMI20051348A1 (it) * | 2005-07-14 | 2007-01-15 | Indena Spa | Analoghi della camptotecina loro processo di ottenimento loro uso e formulazioni che li contengono |
CN100339377C (zh) * | 2005-09-05 | 2007-09-26 | 合肥中科大生物技术有限公司 | 喜树碱衍生物及其制备 |
CN1319971C (zh) * | 2005-09-09 | 2007-06-06 | 合肥中科大生物技术有限公司 | 喜树碱衍生物及其用途 |
US9888690B2 (en) * | 2011-06-22 | 2018-02-13 | Council Of Scientific & Industrial Research | Insecticidal compounds from Nothapodites foetida and process for the extraction thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1269862B (it) * | 1994-05-30 | 1997-04-15 | Indena Spa | Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono |
-
1996
- 1996-05-10 IT IT96MI000944A patent/IT1283635B1/it active IP Right Grant
-
1997
- 1997-05-02 CN CN97194492A patent/CN1082509C/zh not_active Expired - Fee Related
- 1997-05-02 AU AU28901/97A patent/AU715482B2/en not_active Ceased
- 1997-05-02 JP JP54044797A patent/JP3483257B2/ja not_active Expired - Fee Related
- 1997-05-02 ES ES97922937T patent/ES2169389T3/es not_active Expired - Lifetime
- 1997-05-02 CZ CZ19983620A patent/CZ287901B6/cs not_active IP Right Cessation
- 1997-05-02 US US09/155,960 patent/US6121277A/en not_active Expired - Fee Related
- 1997-05-02 WO PCT/EP1997/002244 patent/WO1997043290A1/en not_active Application Discontinuation
- 1997-05-02 SK SK1540-98A patent/SK283050B6/sk not_active IP Right Cessation
- 1997-05-02 RU RU98122224/04A patent/RU2169149C2/ru not_active IP Right Cessation
- 1997-05-02 EP EP97922937A patent/EP0912573B1/en not_active Expired - Lifetime
- 1997-05-02 PT PT97922937T patent/PT912573E/pt unknown
- 1997-05-02 CA CA002253914A patent/CA2253914C/en not_active Expired - Fee Related
- 1997-05-02 KR KR1019980709040A patent/KR20000010893A/ko not_active Application Discontinuation
- 1997-05-02 DE DE69709357T patent/DE69709357T2/de not_active Expired - Lifetime
- 1997-05-02 PL PL97329765A patent/PL188228B1/pl not_active IP Right Cessation
- 1997-05-02 DK DK97922937T patent/DK0912573T3/da active
- 1997-05-02 AT AT97922937T patent/ATE211140T1/de not_active IP Right Cessation
-
1998
- 1998-11-06 NO NO19985186A patent/NO311839B1/no not_active IP Right Cessation
-
1999
- 1999-10-27 HK HK99104790A patent/HK1019600A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SK154098A3 (en) | 1999-04-13 |
ES2169389T3 (es) | 2002-07-01 |
HK1019600A1 (en) | 2000-02-18 |
PL329765A1 (en) | 1999-04-12 |
CA2253914C (en) | 2002-10-22 |
EP0912573B1 (en) | 2001-12-19 |
PT912573E (pt) | 2002-06-28 |
SK283050B6 (sk) | 2003-02-04 |
EP0912573A1 (en) | 1999-05-06 |
AU715482B2 (en) | 2000-02-03 |
JP3483257B2 (ja) | 2004-01-06 |
ATE211140T1 (de) | 2002-01-15 |
NO311839B1 (no) | 2002-02-04 |
KR20000010893A (ko) | 2000-02-25 |
AU2890197A (en) | 1997-12-05 |
WO1997043290A1 (en) | 1997-11-20 |
US6121277A (en) | 2000-09-19 |
CA2253914A1 (en) | 1997-11-20 |
DK0912573T3 (da) | 2002-04-15 |
IT1283635B1 (it) | 1998-04-23 |
CN1082509C (zh) | 2002-04-10 |
PL188228B1 (pl) | 2004-12-31 |
DE69709357D1 (de) | 2002-01-31 |
ITMI960944A0 (ja) | 1996-05-10 |
RU2169149C2 (ru) | 2001-06-20 |
CN1218474A (zh) | 1999-06-02 |
DE69709357T2 (de) | 2002-08-22 |
NO985186L (no) | 1998-11-06 |
CZ287901B6 (cs) | 2001-03-14 |
ITMI960944A1 (it) | 1997-11-10 |
NO985186D0 (no) | 1998-11-06 |
CZ362098A3 (cs) | 1999-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3803124A (en) | Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives | |
JPH0747593B2 (ja) | ラパマイシンのプロドラッグ | |
KR100640066B1 (ko) | 모메타손 푸로에이트의 제조방법 | |
JP2000503666A (ja) | Mappia foetidaから単離したカンプトセシン―骨格化合物および新規な医薬ならびに治療薬のためのシントンとしてのその使用 | |
SU818487A3 (ru) | Способ получени димерных 4-дезацетил-иНдОлдигидРОиНдОлОВ или иХ СОлЕй | |
US4430269A (en) | 12'-Iodo derivatives of dimeric indole-dihydroindole alkaloids, and process for preparing them | |
JPH085866B2 (ja) | 新規なアコニチン系化合物および鎮痛・抗炎症剤 | |
AU634921B2 (en) | Deacetylcolchicine derivatives | |
JP2663105B2 (ja) | 14α−ヒドロキシ−4−アンドロステン−3,6,17−トリオン水和物結晶及びその製造法 | |
AU644696B2 (en) | Novel process for producing 6-(3-dimethylaminopropionyl) forskolin | |
JP2640239B2 (ja) | プロトスタ−13(17)エン−3,16−ジオン化合物 | |
JPH0745498B2 (ja) | t−ブチルエルゴリン誘導体 | |
EP0490311B1 (en) | Derivatives of 10,11,12,13-tetra-hydrodesmycosin, processes for preparation, and use thereof in obtaining pharmaceuticals | |
JPS6318590B2 (ja) | ||
JPH03176473A (ja) | ピリジン―n―オキシド誘導体及びその製法 | |
HU181745B (en) | Process for producing new vinblastin and leurosidin derivatives | |
JPS60260540A (ja) | ジフタル酸エステル誘導体及びその製造法,並びにこれを有効成分とする抗潰瘍剤 | |
JP3134010B2 (ja) | デスアラニンベナノマイシンa誘導体およびそれらの製造法 | |
JPS6159637B2 (ja) | ||
JPH0343261B2 (ja) | ||
JPH0219819B2 (ja) | ||
JPS62142174A (ja) | 10/11−ブロム−14,15−ジヒドロ−14β−ヒドロキシ−(3α,16α)−エブルナメニン−14−カルボン酸メチル化合物の製造方法 | |
LU86486A1 (de) | Verfahren zur herstellung von 10 -methoxy-6-methylergolin-derivaten und ihren saeureadditionssalzen | |
JPH09249681A (ja) | 6−o−(2−アセトアミドエチルホスホニル)−d−マンノピラノシド誘導体、及びその製造法 | |
JPS61172891A (ja) | アントラサイクリン類エステルの製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071017 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081017 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091017 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091017 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101017 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101017 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |